Drug
Talabostat mesylate clinical trials
A product of Talabostat; its studies count on that page too.
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 3
Point Therapeutics (3) · National Institutes of Health Clinical Center (CC) (1) · M.D. Anderson Cancer Center (1) · BioXcel Therapeutics Inc (1) · University of Nebraska (1)
Often tested with
Tested in the same studies.
Rituximab (1) · Carboplatin (1) · Temozolomide (1) · Pembrolizumab (1) · Docetaxel (1) · Gemcitabine (1)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Talabostat
Studies
Open first, then newest update. How each study uses talabostat mesylate is read from its arms, and is right about nine times in ten.
Testing it · 7
- A Pilot Study of BXCL701 in Patients With Pancreatic CancerWithdrawnEarly Phase 1BioXcel Therapeutics IncNCT04123574Written as Talabostat Mesylate
- Talabostat and Pembrolizumab for the Treatment of Advanced Solid CancersTerminatedPhase 2M.D. Anderson Cancer CenterNCT04171219Written as Talabostat Mesylate
- Talabostat in Treating Patients With Metastatic Kidney CancerWithdrawnPhase 2University of NebraskaNCT00489710Written as talabostat mesylate
- Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2Point TherapeuticsNCT00086203Written as Talabostat mesylate (PT-100) tablets
- Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid TumorsCompletedPhase 1National Institutes of Health Clinical Center (CC)NCT00303940Written as talabostat mesylate
- Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based ChemotherapyTerminatedPhase 3Point TherapeuticsNCT00243204Written as talabostat mesylate
- Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the PancreasTerminatedPhase 2Point TherapeuticsNCT00116389Written as talabostat mesylate tablets
Codes
What other systems call talabostat mesylate · ClinicalTrials.gg INT033303
- Wikidata Q27291679talabostat mesylateOne source Wikidata
- NCI Thesaurus C80682Talabostat MesylateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27291679 | talabostat mesylate | One source Wikidata |
| NCI Thesaurus | C80682 | Talabostat Mesylate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.